NCT00598156 - Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva | Biotech Hunter

Enrollment

249

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

August 31, 2012

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

erlotinib (Tarceva)

Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)

DRUG

bevacizumab (Avastin)

Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)

Trial Locations (15)

Lund University Hospital, Department of Oncology, Lund

Vejle Hospital, Department of Oncology, Copenhagen

Esbjerg Hospital, Esbjerg

Herning Hospital, Herning

Hillerod Hospital, Department of Oncology, Hillerød

Odense Hospital, Department of Oncology, Odense

Roskilde Hospital, Department of Oncology, Roskilde

Ryhov Hospital, Department of Oncology, Jönköping

Kalmar Hospital, Department of Oncology, Kalmar

University Hospital MAS, Malmo

Karolinska University Hospital, Department of Oncology, Stockholm

Sundsvall Hospital, Department of Oncology, Sundsvall

University Hospital of Norrland, Department of Oncology, Umeå

Akademiska Hospital, Department of Oncology, Uppsala

Vaxjo Hospital, Department of Oncology, Vaxjo

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Lund University Hospital

OTHER